In an open-label randomized trial, a polypill containing three types of heart failure medication (metoprolol, spironolactone and empagliflozin) improved left ventricular ejection fraction and resulted in a smaller number of heart failure hospitalizations or emergency room visits at 6 months, as compared to enhanced usual care.